Tyra Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	77.39	91.97	58.01	251.21	302.18
Short-Term Investments	178.62	249.48	145.46	-	-
Cash & Short-Term Investments	256	341.44	203.47	251.21	302.18
Cash Growth	-25.02%	67.81%	-19.00%	-16.87%	1884.90%
Other Current Assets	9.45	6.02	8.2	6.08	1.88
Total Current Assets	265.45	347.46	211.67	257.29	304.06
Net Property, Plant & Equipment	6.89	7.72	8.15	3.54	2.09
Other Long-Term Assets	10.27	8.38	6.03	5.35	0.56
Total Assets	282.61	363.56	225.86	266.18	306.7
Accounts Payable	1.18	0.59	4.66	1.15	0.6
Accrued Expenses	16.44	13.59	10.39	4.42	2.82
Current Portion of Leases	0.47	0.41	0.28	0.14	0.2
Total Current Liabilities	18.09	14.59	15.33	5.7	3.62
Long-Term Leases	5.34	5.81	6.22	2.48	0.98
Other Long-Term Liabilities	-	0	0.05	0.17	0.37
Total Long-Term Liabilities	5.34	5.81	6.26	2.65	1.35
Total Liabilities	23.43	20.41	21.6	8.35	4.96
Common Stock	0.01	0.01	0	0	0
Additional Paid-in Capital	630.04	593.69	368.71	353.52	342.1
Accumulated Other Comprehensive Income	0.39	0.77	0.38	-	-
Retained Earnings	-371.26	-251.31	-164.83	-95.7	-40.37
Total Common Shareholders' Equity	259.18	343.15	204.26	257.83	301.74
Shareholders' Equity	259.18	343.15	204.26	257.83	301.74
Total Liabilities & Equity	282.61	363.56	225.86	266.18	306.7
Total Debt	5.81	6.22	6.5	2.62	1.18
Net Cash (Debt)	250.19	335.22	196.97	248.59	301
Net Cash Growth	-25.36%	70.19%	-20.76%	-17.41%	1895.75%
Net Cash Per Share	4.20	5.86	4.61	5.93	21.84
Book Value	259.18	343.15	204.26	257.83	301.74
Book Value Per Share	4.35	6.00	4.78	6.16	21.90
Tangible Book Value	259.18	343.15	204.26	257.83	301.74
Tangible Book Value Per Share	4.35	6.00	4.78	6.16	21.90

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q